[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL: Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg; 2005 Mar;21(2):92-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture.
  • PURPOSE: To determine incidence and distribution of conjunctival epithelial involvement by eyelid sebaceous carcinoma and to make recommendations regarding its management.
  • METHODS: The medical records were reviewed retrospectively on patients with histopathologically confirmed sebaceous carcinoma of the eyelids managed at the Oncology Service at Wills Eye Hospital.
  • Those tumors with involvement of the conjunctival epithelium were identified and selected for further study.
  • The incidence and distribution of epithelial involvement was determined, based on histopathology of resected tumors and map biopsies.
  • Based on these findings and personal surgical experience, recommendations are made regarding management of eyelid sebaceous carcinoma with involvement of the conjunctival epithelium.
  • RESULTS: Of 60 patients with sebaceous carcinoma, epithelial involvement of the conjunctiva was identified in 28 (47%).
  • Map biopsies, combined with cryotherapy, topical chemotherapy, local surgical resection, and orbital exenteration, were used to achieve local control.
  • CONCLUSIONS: Eyelid sebaceous carcinoma was found to exhibit epithelial involvement of the conjunctiva in 47% of cases, predominantly in the superior tarsal and fornical conjunctiva and less often in the inferior tarsal conjunctiva, caruncle, and cornea.
  • Treatment of this condition is challenging, and map biopsy, cryotherapy, topical chemotherapy, and newer surgical methods are being used more often by our group.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma in Situ / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryotherapy. Humans. Incidence. Ophthalmologic Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778660.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Poothullil AM, Colby KA: Topical medical therapies for ocular surface tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):161-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical medical therapies for ocular surface tumors.
  • We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B.
  • One hundred sixty patients with histologically or cytologically proven epithelial and melanocytic tumors were identified in the literature.
  • Topical agents were used as both primary and adjuvant therapy.
  • Rates of tumor regression for CIN and squamous cell carcinoma ranged from 80 to 96%, and 70% of pigmented tumors regressed after an average follow-up of 27 months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymphoma / drug therapy. Lymphoma / pathology. Mitomycin / administration & dosage. Mitomycin / adverse effects. Recombinant Proteins. Sebaceous Gland Neoplasms / drug therapy. Sebaceous Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912014.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


Advertisement
3. Holbach LM, Pogorelov P, Kruse FE: [Differential diagnosis and treatment options for conjunctival tumors]. Ophthalmologe; 2007 Jun;104(6):521-38; quiz 538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis and treatment options for conjunctival tumors].
  • The diagnostic classification of most conjunctival tumors is based on case history, inspection, and examination with the slit lamp microscope.
  • Pigmented and nonpigmented melanocytic nevi are the most frequent conjunctival tumors.
  • Essential in practice is the histopathological confirmation of the clinical diagnosis, e.g., distinguishing between nonpigmented melanomas and sebaceous gland carcinomas with a pagetoid growth pattern or squamous cell carcinomas.
  • Depending on the course and findings, the following therapeutic measures can be indicated: cryotherapy, chemotherapy, radiotherapy, modified enucleation, orbital exenteration, or a combination of different methods.
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Conjunctiva / pathology. Diagnosis, Differential. Humans. Lymphatic Metastasis / pathology. Melanoma / diagnosis. Melanoma / pathology. Melanoma / therapy. Neoplasm Staging. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Nevus, Pigmented / therapy. Ophthalmoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmologe. 2002 Jun;99(6):490-507; quiz 508-9 [12125420.001]
  • [Cites] Orbit. 2000 Mar;19(1):13-19 [12045960.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Aug;242(8):674-8 [15224213.001]
  • [Cites] Klin Monbl Augenheilkd. 1999 Oct;215(4):263-5 [10572892.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):163-7 [11815341.001]
  • [Cites] Klin Monbl Augenheilkd. 1995 Oct;207(4):239-46 [8587298.001]
  • [Cites] Klin Monbl Augenheilkd. 1987 Feb;190(2):105-8 [3553717.001]
  • [Cites] Klin Monbl Augenheilkd. 2001 Apr;218(4):269-72 [11392273.001]
  • [Cites] Klin Monbl Augenheilkd. 2002 Jun;219(6):462-4 [12136445.001]
  • [Cites] Curr Opin Ophthalmol. 1995 Aug;6(4):39-43 [10150881.001]
  • [Cites] Br J Ophthalmol. 2001 Jun;85(6):658-61 [11371482.001]
  • [Cites] Klin Monbl Augenheilkd. 1994 Oct;205(4):242-3 [7823524.001]
  • [Cites] Arch Ophthalmol. 2000 Oct;118(10):1437-40 [11030832.001]
  • [Cites] Hum Mutat. 2006 Feb;27(2):155-62 [16395674.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1985;223(3):164-7 [2993107.001]
  • [Cites] Klin Monbl Augenheilkd. 1986 Aug;189(2):128-32 [3531699.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Ophthalmologe. 2002 May;99(5):394-411; quiz 412-3 [12043298.001]
  • [Cites] Ophthalmologe. 2003 Sep;100(9):708-12 [14504895.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Am J Ophthalmol. 2002 Jul;134(1):147-8 [12095833.001]
  • [Cites] Eur J Ophthalmol. 1992 Jan-Mar;2(1):3-9 [1322210.001]
  • [Cites] Ophthalmologe. 2006 Feb;103(2):124-8 [16047150.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Klin Monbl Augenheilkd. 1985 Sep;187(3):212-4 [2415746.001]
  • [Cites] Arch Ophthalmol. 2003 Dec;121(12):1776-9 [14662600.001]
  • [Cites] J Fr Ophtalmol. 1995;18(6-7):481-3 [7560791.001]
  • [Cites] Br J Ophthalmol. 1997 Feb;81(2):168 [9059254.001]
  • (PMID = 17530261.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement